{"id":"pravastatin-rosuvastatin","safety":{"commonSideEffects":[{"rate":"1–5","effect":"Muscle pain or myalgia"},{"rate":"1–3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"2–5","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"1–3","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These are statins that competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. By reducing hepatic cholesterol production, they lower circulating LDL cholesterol and triglycerides while modestly increasing HDL cholesterol. This reduces atherosclerotic plaque formation and cardiovascular event risk.","oneSentence":"Both pravastatin and rosuvastatin inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:03.313Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"},{"name":"Reduction of myocardial infarction and stroke risk"}]},"trialDetails":[{"nctId":"NCT06553157","phase":"PHASE1, PHASE2","title":"Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Minia University","startDate":"2024-09-01","conditions":"Solid Tumors, Ototoxicity","enrollment":56},{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":"Hypercholesterolaemia","enrollment":520},{"nctId":"NCT06856772","phase":"PHASE4","title":"Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial","status":"NOT_YET_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-02-28","conditions":"Cardiovascular Diseases (CVD), Drug Effect, Atherosclerosis Cardiovascular Disease","enrollment":42000},{"nctId":"NCT03127631","phase":"NA","title":"A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients","status":"RECRUITING","sponsor":"McMaster University","startDate":"2015-10-21","conditions":"Prostate Cancer, Cardiovascular Disease","enrollment":6000},{"nctId":"NCT06785740","phase":"","title":"Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2024-11-01","conditions":"Ischemic Stroke, TIA","enrollment":300},{"nctId":"NCT06785727","phase":"PHASE4","title":"StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Prof. dr. Nathalie van der Velde","startDate":"2025-02-01","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":612},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT05285085","phase":"","title":"Real World Evidence Study of Statin Use in Brazil","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2021-11-19","conditions":"Cardiovascular Diseases, Myocardial Infarction, Stroke","enrollment":2133900},{"nctId":"NCT01563731","phase":"PHASE4","title":"Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2013-04","conditions":"Stroke, Transient Ischemic Attack, Hypertension","enrollment":200},{"nctId":"NCT06262685","phase":"PHASE4","title":"Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2024-03-04","conditions":"Cardiovascular Diseases, Dyslipidemias, Statin Adverse Reaction","enrollment":216},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT02841774","phase":"PHASE2","title":"High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV","status":"COMPLETED","sponsor":"Matthew Feinstein","startDate":"2016-11","conditions":"HIV Infection, Coronary Heart Disease","enrollment":10},{"nctId":"NCT05565976","phase":"PHASE2, PHASE3","title":"Dapagliflozin Effect in Cognitive Impairment in Stroke Trial","status":"UNKNOWN","sponsor":"Jaime Daniel Mondragon","startDate":"2020-08-01","conditions":"Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular","enrollment":270},{"nctId":"NCT04608344","phase":"PHASE1","title":"Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-11-04","conditions":"Rheumatoid Arthritis","enrollment":27},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT00730132","phase":"","title":"Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-01","conditions":"Coronary Heart Disease, Hypercholesterolemia","enrollment":712},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT02072161","phase":"PHASE2","title":"Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":133},{"nctId":"NCT03801733","phase":"PHASE1","title":"Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2018-06-17","conditions":"Drug Interaction Potentiation","enrollment":134},{"nctId":"NCT01872845","phase":"NA","title":"A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2013-06-12","conditions":"Coronary Artery Occlusive Disease","enrollment":671},{"nctId":"NCT00127218","phase":"PHASE3","title":"High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2003-09","conditions":"Atherosclerosis, Cardiovascular Disease","enrollment":145},{"nctId":"NCT01259791","phase":"NA","title":"Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2010-09","conditions":"Statin Myopathy","enrollment":10},{"nctId":"NCT00850460","phase":"PHASE4","title":"Quality of Life in Patients With Statin-Associated Myopathy","status":"TERMINATED","sponsor":"Rockefeller University","startDate":"2009-02","conditions":"Statin Adverse Reaction","enrollment":14},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":216},{"nctId":"NCT00532311","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2007-07","conditions":"Hypercholesterolemia","enrollment":411},{"nctId":"NCT02518516","phase":"","title":"High Potency Statins and Acute Kidney Injury","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2011-01","conditions":"Hypercholesterolemia","enrollment":2067639},{"nctId":"NCT02518503","phase":"","title":"High Potency Statins and the Risk of Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-07","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Disease","enrollment":136966},{"nctId":"NCT01972178","phase":"PHASE2","title":"Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia","status":"TERMINATED","sponsor":"Pronova BioPharma","startDate":"2013-11","conditions":"Dyslipidemia","enrollment":113},{"nctId":"NCT02305355","phase":"PHASE4","title":"Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia","status":"COMPLETED","sponsor":"Kuhnil Pharmaceutical Co., Ltd.","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2, Hypertriglycemia","enrollment":68},{"nctId":"NCT00631189","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Type IIa and IIb Hypercholesterolaemia","enrollment":668},{"nctId":"NCT01816997","phase":"PHASE4","title":"The Statins on Glucose Homeostasis in Subjects With Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2012-01","conditions":"Diabetes","enrollment":160},{"nctId":"NCT01634906","phase":"NA","title":"Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy","status":"COMPLETED","sponsor":"Sint Franciscus Gasthuis","startDate":"2012-07","conditions":"Hyperlipidemia, Atherosclerosis","enrollment":55},{"nctId":"NCT00117494","phase":"PHASE4","title":"Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2005-10","conditions":"Hyperlipidemia, HIV Infections","enrollment":86},{"nctId":"NCT01173939","phase":"NA","title":"Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments","status":"TERMINATED","sponsor":"Positive Trial Group","startDate":"2010-07","conditions":"Hypercholesterolemia, Type 2 Diabetes, Hypertension","enrollment":10000},{"nctId":"NCT01325818","phase":"PHASE4","title":"The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris","status":"UNKNOWN","sponsor":"Yokohama City University Medical Center","startDate":"2011-03","conditions":"Coronary Disease, Hypercholesterolemia","enrollment":150},{"nctId":"NCT00214604","phase":"PHASE3","title":"Type III Dysbetalipoproteinemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-02","conditions":"Hyperlipoproteinemia Type III","enrollment":30},{"nctId":"NCT01011127","phase":"","title":"Different Metabolic Effects of Statins","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2009-12","conditions":"Hypercholesterolemia","enrollment":""},{"nctId":"NCT00718796","phase":"PHASE3","title":"Naturopathic Treatment for the Prevention of Cardiovascular Disease","status":"COMPLETED","sponsor":"The Canadian College of Naturopathic Medicine","startDate":"2008-04","conditions":"Cardiovascular Disease","enrollment":300},{"nctId":"NCT00654537","phase":"PHASE3","title":"STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2001-04","conditions":"Hypercholesterolemia","enrollment":5625},{"nctId":"NCT00464503","phase":"NA","title":"Statins and the Urinary Proteome","status":"COMPLETED","sponsor":"Universiteit Antwerpen","startDate":"2007-09","conditions":"Statin Induced Proteinuria","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"pravastatin, rosuvastatin","genericName":"pravastatin, rosuvastatin","companyName":"Yokohama City University Medical Center","companyId":"yokohama-city-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Both pravastatin and rosuvastatin inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of myocardial infarction and stroke risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}